Regulatory T cells in cancer immunosuppression - implications for anticancer therapy (Q91297827)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30705439%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

title

Regulatory T cells in cancer immunosuppression - implications for anticancer therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30705439%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30705439%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

author name string

Yosuke Togashi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30705439%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

Kohei Shitara

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30705439%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

publication date

1 June 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30705439%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

21 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30705439%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30705439%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30705439%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

page(s)

356-371

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30705439%20AND%20SRC:MED&resulttype=core&format=json

An essential role for Scurfin in CD4+CD25+ T regulatory cells

21 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Control of regulatory T cell development by the transcription factor Foxp3

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

FOXP3+ regulatory T cells in the human immune system

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Regulatory T cells exert checks and balances on self tolerance and autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Foxp3+ follicular regulatory T cells control the germinal center response.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

IL-10 Potentiates Differentiation of Human Induced Regulatory T Cells via STAT3 and Foxo1.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

The role of T-cell receptor recognition of peptide:MHC complexes in the formation and activity of Foxp3⁺ regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

A two-step process for thymic regulatory T cell development.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

The role of interleukin-2 during homeostasis and activation of the immune system

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Aire-dependent thymic development of tumor-associated regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Function of a Foxp3 cis-element in protecting regulatory T cell identity

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Foxp3 transcription factor is proapoptotic and lethal to developing regulatory T cells unless counterbalanced by cytokine survival signals

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Promiscuous Foxp3-cre activity reveals a differential requirement for CD28 in Foxp3⁺ and Foxp3⁻ T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Novel Foxo1-dependent transcriptional programs control T(reg) cell function

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Foxp3 exploits a pre-existent enhancer landscape for regulatory T cell lineage specification

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Transcription factors Foxo3a and Foxo1 couple the E3 ligase Cbl-b to the induction of Foxp3 expression in induced regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Epigenetic control of the foxp3 locus in regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Differential roles of epigenetic changes and Foxp3 expression in regulatory T cell-specific transcriptional regulation

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Interleukin-7 receptor expression: intelligent design

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

CTLA-4 control over Foxp3+ regulatory T cell function

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

The inhibitory cytokine IL-35 contributes to regulatory T-cell function

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Interleukin-35 Limits Anti-Tumor Immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Human T regulatory cells can use the perforin pathway to cause autologous target cell death

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Next-generation insights into regulatory T cells: expression profiling and FoxP3 occupancy in Human

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Molecular mechanisms of T cell co-stimulation and co-inhibition

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8 T cells in the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

The immune contexture in human tumours: impact on clinical outcome

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Inflammatory regulatory T cells in the microenvironments of ulcerative colitis and colon carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

FOXP3 defines regulatory T cells in human tumor and autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Treg Depletion Licenses T Cell-Driven HEV Neogenesis and Promotes Tumor Destruction

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Suppression from beyond the grave.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed toward public sequences

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

The epigenetic landscape of T cell exhaustion.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Impact of oncogenic pathways on evasion of antitumour immune responses.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Regulatory T cells increase the avidity of primary CD8+ T cell responses and promote memory.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Detection of self-reactive CD8⁺ T cells with an anergic phenotype in healthy individuals

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Genetic basis for clinical response to CTLA-4 blockade in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Letter

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Continuous requirement for the TCR in regulatory T cell function

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

PD-1 marks dysfunctional regulatory T cells in malignant gliomas

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Myeloid-Derived Suppressor Cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Tumour-associated macrophages as treatment targets in oncology.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Control of the immune response by pro-angiogenic factors

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Immunoregulatory functions and the therapeutic implications of GARP-TGF-β in inflammation and cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Revisiting IL-2: Biology and therapeutic prospects

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

OX40 is required for regulatory T cell-mediated control of colitis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

OX40 is a potent immune-stimulating target in late-stage cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Continuous T cell receptor signals maintain a functional regulatory T cell pool.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

IDO is a nodal pathogenic driver of lung cancer and metastasis development

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

TGF-β: duality of function between tumor prevention and carcinogenesis.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Foxp3-independent mechanism by which TGF-β controls peripheral T cell tolerance.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Heat Shock Proteins as Immunomodulants

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

HSP70 enhances immunosuppressive function of CD4(+)CD25(+)FoxP3(+) T regulatory cells and cytotoxicity in CD4(+)CD25(-) T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

The secret ally: immunostimulation by anticancer drugs

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Photodynamic therapy downregulates the function of regulatory T cells in patients with esophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

IL-1β promotes Th17 differentiation by inducing alternative splicing of FOXP3.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Human CD8+ T lymphocyte clones specific for T cell receptor V beta families expressed on autologous CD4+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Tissue-Specific Roles of NKT Cells in Tumor Immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Identification of Regulatory Foxp3+ Invariant NKT Cells Induced by TGF-

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Foxp3 expression in macrophages associated with RENCA tumors in mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Lack of Foxp3+ macrophages in both untreated and B16 melanoma-bearing mice

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Macrophages have no lineage history of Foxp3 expression.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Regulatory B cells: origin, phenotype, and function.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Allergen-specific responses of CD19(+)CD5(+)Foxp3(+) regulatory B cells (Bregs) and CD4(+)Foxp3(+) regulatory T cell (Tregs) in immune tolerance of cow milk allergy of late eczematous reactions

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0175-7

7 January 2021

10.1038/S41571-019-0175-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30705439%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

1 reference